oru.sePublications
Change search
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf
TRIM24 as Independent Prognostic Marker in Prostate Cancer
University Medical Center Schleswig-Holstein, Leibniz Center for Medicine and Biosciences, Lübeck and Borstel, Germany.
Klinik am Eicher Alb Fils Kliniken, Goeppingen, Germany.
University Hospital Schleswig-Holstein, Lübeck, Germany.
Klinik am Eichert Alb Fils Kliniken, Goeppingen, Germany.
Show others and affiliations
2018 (English)In: Modern Pathology, ISSN 0893-3952, E-ISSN 1530-0285, Vol. 31, no Suppl. 2, p. 372-373Article in journal, Meeting abstract (Other academic) Published
Abstract [en]

Background: Simply applicable biomarkers for prostate cancer (PCa) predicting the clinical course are urgently needed. Recently, TRIM24 has been identified to promote androgen-receptor signaling and to correlate with poor outcome. Based on these data, we validated TRIM24 as a prognostic biomarker for PCa.

Design: We performed TRIM24 immunohistochemistry on two independent cohorts including a total of 806 primary tumors, 26 locally advanced/recurrent tumors, 30 lymph node metastases, 30 distant metastases and 129 benign prostatic samples from 497 patients. Expression data were correlated with clinic-pathological data including biochemical recurrence free survival (bRFS) as endpoint.

Results: Benign samples show no/low TRIM24 expression in 94%, while tumors demonstrate significantly higher levels. Strongest expression is observed in metastatic tumors. In multivariate analyses, TRIM24 up-regulation correlates with shorter bRFS independent of other prognostic parameters. 5-(10-) year bRFS rates for TRIM24 negative, low, medium and high expressing tumors are 93.1(93.1)%, 75.4(68.5)%, 54.9(47.5)% and 43.1(32.3)%, respectively. Of interest, tumors diagnosed as indolent disease, TRIM24 expression stratifies patients into specific risk groups. Increased TRIM24 expression associates with higher Grade Group, positive nodal status and extraprostatic tumor growth.

Conclusions: Using two large independent cohorts, we found that TRIM24 expression predicts patients’ risk to develop disease recurrence with high accuracy and independently from other established prognostic markers. To our knowledge, TRIM24 is the first prognostic biomarker to be independent, accurate and reproducible on three different primary PCa cohorts. Thus, we strongly suggest introducing TRIM24 in clinical routine as a simple immunohistochemical test.

Place, publisher, year, edition, pages
Nature Publishing Group, 2018. Vol. 31, no Suppl. 2, p. 372-373
National Category
Cancer and Oncology
Identifiers
URN: urn:nbn:se:oru:diva-66846DOI: 10.1038/modpathol.2018.10ISI: 000429308602377OAI: oai:DiVA.org:oru-66846DiVA, id: diva2:1203198
Conference
107th Annual Meeting of the United-States-and-Canadian-Academy-of-Pathology (USCAP), Vancouver, Canada, March 17-23, 2018
Available from: 2018-05-02 Created: 2018-05-02 Last updated: 2018-09-06Bibliographically approved

Open Access in DiVA

No full text in DiVA

Other links

Publisher's full text

Authority records BETA

Carlsson, JessicaSvensson, MariaAndrén, Ove

Search in DiVA

By author/editor
Carlsson, JessicaSvensson, MariaAndrén, Ove
By organisation
School of Medical SciencesÖrebro University Hospital
In the same journal
Modern Pathology
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar

doi
urn-nbn

Altmetric score

doi
urn-nbn
Total: 231 hits
CiteExportLink to record
Permanent link

Direct link
Cite
Citation style
  • apa
  • ieee
  • modern-language-association-8th-edition
  • vancouver
  • Other style
More styles
Language
  • de-DE
  • en-GB
  • en-US
  • fi-FI
  • nn-NO
  • nn-NB
  • sv-SE
  • Other locale
More languages
Output format
  • html
  • text
  • asciidoc
  • rtf